Lineage Cell Therapeutics, Inc. Appoints George A. Samuel III as General Counsel and Corporate Secretary
September 01, 2021 at 05:30 pm IST
Share
Lineage Cell Therapeutics, Inc. announced that it has appointed George A. Samuel III as Lineage’s General Counsel and Corporate Secretary. Mr. Samuel will lead the Company’s legal operations, bringing extensive corporate, transactional, intellectual property and commercial expertise which spans nearly 15 years across the life sciences and technology sectors as well as in private practice. Prior to joining Lineage, Mr. Samuel most recently served as Director, Senior Counsel for Lytx, Inc., where he managed the commercial legal operations for an international video telematics SaaS company.
Lineage Cell Therapeutics, Inc. is a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs. The Companyâs programs are based on its cell-based technology platform and associated development and manufacturing capabilities. From this platform, the Company designs, develops, manufactures, and tests specialized human cells with anatomical and physiological functions. Its neuroscience focused pipeline includes OpRegen, a retinal pigment epithelial cell therapy in phase II a development, for the treatment of geographic atrophy secondary to age-related macular degeneration; OPC1, an oligodendrocyte progenitor cell therapy in phase I/II a development for the treatment of spinal cord injuries; ANP1, an auditory neuronal progenitor cell therapy for the potential treatment of auditory neuropathy; PNC1, a photoreceptor neural cell therapy for the potential treatment of vision loss due to photoreceptor dysfunction or damage; and RND1.